Taken from an interview with Hannah Blake of Pharmaphorum While the pharma industry may believe drug discovery has been fully optimized, David Leahy disagrees. As the CEO and co-founder of Molplex, David shares his vision with us – to drive down productivity costs from £20 million to £1 million for each new drug candidate.
The revolution in information technology and emerging developments such as the semantic web, cloud computing as well as community data and software resources is now creating the right circumstances for a second wave of change. This change will be driven by solutions for managing information, extracting knowledge and making decisions in virtual organisations which will create opportunities for new entrants to this very valuable market, especially those with strong IT expertise. The new entrants will be “micro-Pharmas” that minimise fixed costs through accessing on demand, pay-as-you-go laboratory and computing services and exploit Web 2.0 technologies to access globally available services and expertise “on demand”.read on →
Tags2.0 technologies AstraZeneca PLC autonomous agents BioMoby Biotechnology Biotechnology and Pharmaceuticals business Cancer Research UK ChEMBL chemical and biological data Cheminformatics Cloud Computing combinatorial search Cyprotex David Leahy drug design Drug development Drug Discovery Expert information technology Medicinal chemistry Microsoft Research Molplex on demand services Open Science Pharma pharmaceutical Pharmaceutical companies Pharmaceutical industry Pharmaceutical sciences Research Research and development semantic web Web 2.0 Web service